Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

And that story is still being written. Now, Geyer and his colleagues are investigating a promising new antibody-drug candidate called trastuzumab deruxtecan, or T-DXd, for certain groups of ...

And that story is still being written. Now, Geyer and his colleagues are investigating a promising new antibody-drug candidate called trastuzumab deruxtecan, or T-DXd, for certain groups of ...